Quantum BioPharma (XCNQ:QNTM) EBITDA Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Quantum BioPharma's EBITDA for the three months ended in Dec. 2024 was C$-7.59 Mil. Quantum BioPharma's Revenue for the three months ended in Dec. 2024 was C$0.00 Mil. Therefore, Quantum BioPharma's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

Quantum BioPharma EBITDA Margin % Historical Data

The historical data trend for Quantum BioPharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma EBITDA Margin % Chart

Quantum BioPharma Annual Data

Trend

Aug15

Aug16

Aug17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBITDA Margin %

Get a 7-Day Free Trial

Quantum BioPharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Quantum BioPharma's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Quantum BioPharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quantum BioPharma's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quantum BioPharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Quantum BioPharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Quantum BioPharma's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-20.483	/	0
	=	%

Quantum BioPharma's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-7.589	/	0
	=	%

Quantum BioPharma (XCNQ:QNTM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Quantum BioPharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantum BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (XCNQ:QNTM) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

QNTM:USA 0K91:Germany

Address

55 University Avenue, Suite 1003, Toronto, ON, CAN, M5J 2H7

Website

https://www.fsdpharma.com

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.